Top Page
Verrica Pharmaceuticals
(NASDAQ:VRCA)
Verrica Pharmaceuticals (VRCA) vs. SPDR S&P 500 ETF (SPY)
Verrica Pharmaceuticals Business Overview & Revenue Model
Verrica Pharmaceuticals Earnings Call Summary
Verrica Pharmaceuticals Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 7.57M | 5.12M | 9.03M | 12.00M | 0.00 |
| Gross Profit | 5.71M | 4.38M | 8.31M | 11.53M | -229.00K |
| EBITDA | -65.90M | -62.20M | -21.60M | -30.31M | -39.43M |
| Net Income | -76.58M | -67.00M | -27.68M | -38.90M | -45.50M |
Balance Sheet | |||||
| Total Assets | 54.13M | 81.60M | 44.72M | 80.13M | 74.15M |
| Cash, Cash Equivalents and Short-Term Investments | 46.33M | 69.55M | 34.27M | 70.35M | 65.47M |
| Total Debt | 45.94M | 45.51M | 1.53M | 43.41M | 35.31M |
| Total Liabilities | 63.99M | 61.83M | 4.69M | 47.52M | 41.17M |
| Stockholders Equity | -9.86M | 19.76M | 40.03M | 32.60M | 32.99M |
Cash Flow | |||||
| Free Cash Flow | -60.95M | -38.94M | -18.95M | -28.46M | -31.68M |
| Operating Cash Flow | -60.93M | -38.58M | -18.65M | -27.58M | -30.21M |
| Investing Cash Flow | -19.00K | -362.00K | 54.04M | -998.00K | -3.58M |
| Financing Cash Flow | 37.73M | 74.21M | -16.87M | 33.65M | 35.23M |
Verrica Pharmaceuticals Technical Analysis
Verrica Pharmaceuticals Risk Analysis
Verrica Pharmaceuticals Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
50 Neutral | $52.11M | ― | -119.22% | ― | ― | 25.51% | |
47 Neutral | $57.72M | ― | -1546.58% | ― | -19.45% | 31.22% | |
46 Neutral | C$198.38M | -2.33 | -23.14% | 2.83% | 20.73% | -1.08% | |
46 Neutral | $54.28M | ― | -290.21% | ― | -100.00% | 44.28% | |
40 Underperform | $73.77M | ― | -32.66% | ― | ― | 21.33% | |
39 Underperform | $68.02M | ― | -679.15% | ― | -56.88% | -57.57% |
Verrica Pharmaceuticals Corporate Events
On July 24, 2025, Nasdaq notified Verrica Pharmaceuticals that its securities were subject to delisting due to non-compliance with the Minimum Bid Price Requirement. The company implemented a 1-for-10 reverse stock split to increase its stock price, which began trading on a split-adjusted basis on July 25, 2025. As of July 29, 2025, the stock price was $6.24, and the company plans to request a compliance determination after ten days of maintaining the required bid price.
The most recent analyst rating on (VRCA) stock is a Buy with a $120.00 price target. To see the full list of analyst forecasts on Verrica Pharmaceuticals stock, see the VRCA Stock Forecast page.
On July 22, 2025, Verrica Pharmaceuticals Inc. filed a Certificate of Amendment to implement a 1-for-10 reverse stock split, effective July 24, 2025. This move, approved by stockholders on June 5, 2025, will proportionately adjust stock options and warrants, affecting all stockholders equally without changing percentage ownership. The company’s common stock will trade on a split-adjusted basis on The Nasdaq Global Market starting July 25, 2025, reducing the number of outstanding shares from approximately 92.5 million to 9.25 million.
The most recent analyst rating on (VRCA) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Verrica Pharmaceuticals stock, see the VRCA Stock Forecast page.
On June 27, 2025, Verrica Pharmaceuticals amended its collaboration with Torii Pharmaceutical to initiate a global Phase 3 clinical trial for YCANTH® to treat common warts. Torii will provide an $8 million milestone payment and fund the first $40 million of the trial costs. The amendment also includes a $10 million payment if YCANTH is approved for molluscum contagiosum in Japan. This strategic move aims to expand YCANTH’s market presence and strengthen Verrica’s financial position, with the first patient dosing expected in the fourth quarter of 2025.
The most recent analyst rating on (VRCA) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Verrica Pharmaceuticals stock, see the VRCA Stock Forecast page.
On June 10, 2025, Verrica Pharmaceuticals Inc. entered into a sixth amendment and waiver to its Credit Agreement with OrbiMed Royalty & Credit Opportunities IV, LP and other lenders. The amendment includes a waiver of certain covenants related to financial statement qualifications for the quarters ending June 30, 2025, and September 30, 2025, as well as the year ending December 31, 2025. This move allows Verrica Pharmaceuticals to avoid a ‘going concern’ qualification, potentially stabilizing its financial outlook and reassuring stakeholders about its operational continuity.
The most recent analyst rating on (VRCA) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Verrica Pharmaceuticals stock, see the VRCA Stock Forecast page.
On June 5, 2025, Verrica Pharmaceuticals held its annual stockholders meeting where four proposals were considered. All three director nominees were elected, executive compensation was approved, KPMG LLP’s appointment as the accounting firm was ratified, and a potential reverse stock split was authorized, reflecting strong shareholder support for the company’s strategic decisions.
The most recent analyst rating on (VRCA) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Verrica Pharmaceuticals stock, see the VRCA Stock Forecast page.